Parsaclisib

帕萨利司

Report date: 2024/12/25 20:00:50
NME

Base Information

Drug NameParsaclisib
Drug Alias NameINCB-50465IBI-376INCB-050465
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase delta inhibitors
TargetsPhosphatidylinositol 3 kinase delta
Therapy Area/IndicationsSolid tumoursPemphigusPrimary Myelofibrosis +[30] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[26] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesIncyte Corp
China Registration ClassN/A

Develop Information

Active CompaniesQuotient Sciences - Philadelphia LlcIncyte CorpFudan University +[6] 
Inactive CompaniesSharp Corp
Active IndicationsPrimary MyelofibrosisThrombocythemia, EssentialPolycythemia Vera +[11] 
Inactive IndicationsSolid tumoursPemphigusAnemia, Hemolytic, Autoimmune +[19] 

Other Information

ATC CodeN/A
Related LinksN/A